![]() The biochemical observations were supported by histopathological examination of liver sections. As regarding lipid peroxidation markers, administration of low or high dose of olmesartan concomitant with CCl4 exhibited a significant decrease in liver MDA and a significant increase in both GSH and SOD. Hydroxyproline content of the liver showed improvement evidenced by a significant decrease in its level in both olmesartan treated groups when compared with CCl4-treated rats. At the same time, low dose olmesartan treated rats showed a non-significant difference in albumin as compared to model group while high dose olmesartan treated rats showed a significant elevation in serum albumin. Our results revealed that the rats treated with low dose of olmesartan concomitant with CCl4 showed a non-significant decrease in liver enzymes (AST, ALT, ALP) and bilirubin when compared with model group, while the rats treated with high dose of olmesartan concomitant with CCl4 resulted in a significant decrease in the previous parameters. At the same time, there was a significant increase of lipid peroxidation measured as (MDA) and a significant decrease of (GSH) and (SOD) content in the liver tissue homogenate. In addition to a significant elevation of liver fibrosis marker (hydroxyproline content of the liver). Results: CCl4-induced liver fibrosis was manifested by a significant elevation in activities of AST, ALT, ALP and serum bilirubin and a significant decrease in serum albumin. In addition to histopathological examination of liver tissues. Liver function, oxidative stress markers in liver tissues and a marker of liver fibrosis (liver hydroxyproline content) were assessed. At the end of the study period, blood samples and liver tissues were collected and subjected to the biochemical and histopathological examination. Olmesartan groups were given (0.6 and 6 mg/kg/day) via gavage. Except for rats in control groups, all rats were injected subcutaneously with 1ml/kg CCl4 at a ratio of 1:1 with olive oil, twice a week for 12 weeks. Methods : Fifty adult male albino rats were randomly divided into five equal groups, including normal control rats (group I), control vehicle rats (group II), model group (group III), and two treated groups with either low (group IV) or high dose (groupV) of olmesartan medoxomil. Our product offerings include millions of PowerPoint templates, diagrams, animated 3D characters and more.Aim: The aim of the current article was to investigate the possible antifibrotic and antioxidant effects of a new angiotensin II type I receptor blocker, olmesartan medoxomil, using low and high dose on CCl4-induced liver fibrosis. is brought to you by CrystalGraphics, the award-winning developer and market-leading publisher of rich-media enhancement products for presentations. ![]() Then you can share it with your target audience as well as ’s millions of monthly visitors. We’ll convert it to an HTML5 slideshow that includes all the media types you’ve already added: audio, video, music, pictures, animations and transition effects. You might even have a presentation you’d like to share with others. And, best of all, it is completely free and easy to use. Whatever your area of interest, here you’ll be able to find and view presentations you’ll love and possibly download. It has millions of presentations already uploaded and available with 1,000s more being uploaded by its users every day. is a leading presentation sharing website.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |